Comparing Retreatment of ¹⁷⁷Lu-DOTATATE PRRT versus Everolimus in Patients with Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Radiation Medication (Radium-223 Dichloride) versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Radium-223 in Biochemically Recurrent Prostate Cancer

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma

Evaluation of Neuroinflammation FNOS PET/CT in HIV (+) and (-) Subjects with OUD and Healthy Controls

Real-world Experience with Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

Implications of Biological and Procedural Factors of 18-f FDG Uptake by Normal Organs and Neoplastic Lesions

A Study to Test Radium-223 with Docetaxel in Patients with Prostate Cancer

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones